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Inﬂammatory bowel disease (IBD) is a complex multifactorial disease of unknown etiology. Thus, dozens of diﬀerent animal
models of IBD have been developed in past decades. Animal models of IBD are valuable and indispensable tools that provide
a wide range of options for investigating involvement of various factors into the pathogenesis of IBD and to evaluate diﬀerent
therapeutic options. However, the dextran sulphate sodium (DSS-) induced colitis model has some advantages when compared to
otheranimalmodelsofcolitis.Itiswellappreciatedandwidelyusedmodelofinﬂammatoryboweldiseasebecauseofitssimplicity.
It has many similarities to human IBD, which are mentioned in the paper. In spite of its simplicity and wide applicability, there are
also traps that need to be taken into account when using DSS model. As demonstrated in the present paper, various factors may
aﬀect susceptibility to DSS-induced lesions and modify results.
1.Introduction
Inﬂammatory bowel disease (IBD) is a complex multi-
factorial disease [1–3]. It commonly refers to ulcerative
colitis (UC) and Crohn’s disease (CD), the two chronic
conditions that involve inﬂammation of the intestine. IBD
is common in developed countries, with up to 1 in 200
of individuals of Northern European region aﬀected by
these disease [4]. Patients with IBD present several clinically
challengingproblemsforphysicians.Despiterecentadvances
in treatment, there remains a need for a safe, well-tolerated
therapy with a rapid onset, and increased capacity for
maintaining long-term remission [5].
In past decades, dozens of diﬀerent animal models of
IBD have been developed. These models can be broadly
divided into spontaneous colitis models, inducible colitis
models, genetically modiﬁed models, and adoptive transfer
models [6–8]. Although these models do not represent
the complexity of human disease, they are valuable and
indispensable tools that provide a wide range of options
for investigating involvement of various factors into the
pathogenesis of IBD and evaluate diﬀerent therapeutic
options. Chemically induced murine models of intestinal
inﬂammation are one of the most commonly used models
because they are simple to induce, the onset, duration, and
severity of inﬂammation are immediate and controllable.
Both dextran sulphate sodium (DSS) and trinitrobenzene
sulfonic acid (TNBS-) induced colitis are well-established
animal models of mucosal inﬂammation that have been used
for over 2 decades in the study of IBD pathogenesis and
preclinical studies [6–8]. The DSS-induced colitis model has
some advantages when compared to other animal models of
colitis. For example, an acute, chronic, or relapsing model
can be produced easily by changing the concentration of
administration of DSS (and cycle in rats and other strains
of mice). Moreover, dysplasia that resembles the clinical
course of human UC occurs frequently in the chronic phase
of DSS-induced colitis. DSS-induced model for studying
colitis-associated carcinogenesis has been recently reviewed
by others [9, 10]. Furthermore, studies that validated DSS
model by using diﬀerent therapeutic agents for human IBD
show that DSS-induced colitis can be used as a relevant
model for the translation of mice data to human disease
[11]. Thus, the aim of the present paper is to give a concise
introduction of diﬀerent factors that may be involved in the
patogenesis of DSS-induced colitis and need to be taken into
account when using this model. At the same time few aspects
of applicability and further investigation of this model are
mentioned.2 Journal of Biomedicine and Biotechnology
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Figure 1: Schematic simpliﬁed representation of various factors that can inﬂuence the susceptibility, onset, severity, and responsiveness to
DSS-induced colitis.
2. Induction of DSS Colitis
First report on the use of DSS dates back in the year 1985,
when Ohkusa et al. published their investigation on DSS-
induced colitis in hamsters [12]. Thereafter, DSS colitis was
induced also in mice [13]. Today there are numerous studies
using DSS-induced colitis model to investigate pathogenesis
of colitis and diﬀerent factors aﬀecting colitis. Colitis is
induced by addition of DSS to drinking water. Depend-
ing on the concentration, the duration, and frequency of
DSS administration, the animals may develop acute or
chronic colitis or even colitis-induced dysplastic lesions.
Mice show diﬀerential susceptibilities and responsiveness to
DSS-induced colitis. The varying responses to DSS appear
to be dependent on not only DSS (concentration, molec-
ular weight, duration of DSS exposure, manufacturer, and
batch) but also genetic (strain and substrain, gender) and
microbiological (microbiological state and intestinal ﬂora)
factors of animal, which are disscussed in the present paper
(Figure 1). Colitis onset and severity may vary with many
of these factors. Stress can be one of them [14]. Diﬀerences
in the DSS susceptibility do not correlate with diﬀerences in
theconsumptionofDSS-supplementedwater[15].However,
thereisaneedtomonitorDSSconsumption,especiallywhen
animals are exposed to diﬀerent therapeutic strategies that
may lower consumption of DSS (increased ﬂuid intake or
thirst) [16].
3. The Molecular Weightof DSS
DSS is sulfated polysaccharide with a highly variable molec-
ular weight, ranging from 5kDa to up to 1400kDa. It was
found that the molecular weight of DSS is very important
factor in the induction of colitis [17] or colitis-induced
dysplastic lesions (carcinogenicity) [18]. The severity of
colitis [17] and carcinogenic activity [18]d i ﬀers with the
administration of DSS at diﬀerent molecular weights (i.e.,
5kDa, 40kDa, and 500kDa). The most severe colitis in
BALB/c mice was observed when mice were treated with
DSS of 40kDa molecular weight, while mice treated with
DSS of 5kDa developed milder form of colitis. Mice treated
with DSS of 500kDa had no lesions in the large bowel [17].
Similarly, carcinogenic activity in colon was induced by DSS
of54kDa,whileDSSoflarger(520kDa)orsmaller(9.5kDa)
molecular weights induced no carcinogenic activity [18].
Examination of uptake and tissue distribution of DSS by his-
tochemicaltechniquesshowedthatfailureintheinductionof
colitis with 500kDa DSS is due to its high molecular weight
that prevents passage of the molecule through the mucosal
membrane [17]. Molecular weight of DSS can aﬀect location
of colitis as well. Mice treated with 40kDa DSS developed
most severe diﬀuse colitis in the middle and distal third of
thelargebowel,whilemicetreatedwith5kDaDSSdeveloped
relativelypatchylesionsmainlyinthececumanduppercolon
[17].
3.1. Uptake and Tissue Distribution of DSS. The histochem-
ical analyses of uptake and tissue distribution of DSS at
40kDa molecular weight demonstrated that DSS penetrates
the mucosal membrane in the intestine. One day after DSS
treatment small amounts of DSS were found in macrophages
in large bowel and mesenteric lymph nodes and in the liver
Kupﬀer cells. At day 3 DSS was noticed in a few macrophagesJournal of Biomedicine and Biotechnology 3
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Figure 2: (a) Disappearance of crypts. (b) Erosion and phlegmonous inﬂammation of mucosa and submucosa. Kreyberg trichrom stain
(acid mucopolysaccharides are stained blue). C57BL/6JOlaHsd female mice are exposed to 3% DSS solution for 5 days followed by drinking
water for 7 days.
200x
(a)
400x
(b)
Figure 3: (a) Vacuolar hydropic degeneration of cells. (b) Epithelial necrosis, cryptitis, and crypt abscesses. Kreyberg trichrom stain (acid
mucopolysaccharides are stained blue). C57BL/6JOlaHsd female mice exposed to 3% DSS solution for 5 days followed by drinking water for
21 days.
in the spleen and 7 days after the start of 5 day DSS
treatment in the kidney and in a few macrophages in the
small intestine. DSS was seen in the liver Kupﬀer cells even
8w e e k sa f t e rD S Sr e m o v a l[ 19]. During chronic phase of
DSS colitis, considerable amounts of DSS were also found
in the spleen [20]. In other organs and tissues (for instance
brain, lung, heart, thymus, stomach, and duodenum), DSS
was not observed [19]. Major excretion routes of DSS are
urine and feces. Thus, presence of DSS in the epithelial cells
of the proximal renal tubules after 7 days of DSS treatment is
an indication of the excretion process of absorbed DSS [19].
DSS is resistant to degradation by intestinal microﬂora or
theeﬀectsofdiﬀerentpHconditions(4.0–7.5)andanaerobic
incubation [21].
4.ClinicalandHistologicalFeaturesof
DSS-InducedColitis
Clinical and histopathological features of DSS-colitis reﬂect
those seen in human IBD. Acute colitis is usually induced by
continuousadministrationof2–5%DSSforshortperiod(4–
9 days). Chronic colitis may be induced by continuous treat-
mentoflowconcentrationsofDSSorcyclicaladministration
of DSS. For instance, 4 cycles of DSS treatment for 7 days
followedby10daysofwater(Table 4).Clinicalmanifestation
of DSS colitis in acute phase may include weight loss,
diarrhea, occult blood in stools, piloerection, anaemia, and
eventually death. However, clinical manifestations in chronic
phaseofcolitisusuallydonotreﬂectseverityofinﬂammation
or histologic features found in large bowel.
Histological changes in DSS-induced colitis can be clas-
siﬁed as acute (early) and chronic (advanced). Typical histo-
logical changes of acute DSS-colitis are mucin depletion,
epithelial degeneration, and necrosis leading to disappear-
ance of epithelial cells (Figure 2(a)) .T h el a t t e ri sa c c o m -
panied by neutrophils inﬁltration of lamina propria and
submucosa, cryptitis, crypt abscesses (Figures 3(b) and 4),
and phlegmonous inﬂammation in mucosa and submu-
cosa (Figure 2(b)). Usually also shallow erosions appear
(Figure 2(b)). Rarely there is a vacuolar hydropic degener-
ation of cells (Figure 3(a)). Transepithelial migration of neu-
trophils into mucosal epithelium is termed cryptitis. Migra-
tion of numerous neutrophils through mucosal epithelium
into crypt lumen results in the formation of crypt abscess.
Cryptitis and crypt abscesses are common histological fea-
tureofhumanIBDbutrarelyreportedinDSS-inducedcolitis4 Journal of Biomedicine and Biotechnology
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Figure 4:Arrowsdenotecryptabscesses(neutrophils)inthelumenofcrypts.Kreybergtrichromstain(acidmucopolysaccharidesarestained
blue). C57BL/6JOlaHsd male mice are exposed to 3% DSS solution for 5 days followed by drinking water for (a) 7 days and (b) 28 days.
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Figure 5: (a) Mononuclear leucocytes inﬁltration, crypt architectural disarray, and deep mucosal lymphocytosis. (b) Focally there is a
moderate epithelial regeneratory atypia simulating dysplasia (arrow). Kreyberg trichrom stain (acid mucopolysaccharides are stained blue).
C57BL/6JOlaHsd male mice are exposed to 3% DSS solution for 5 days followed by drinking water for 28 days.
using haematoxylin-eosin staining method [22]. In contrast,
we found cryptitis and crypt abscesses in half of DSS-
treated C57BL/6JOlaHsd mice, while in BALB/cAnNHsd
mice cryptitis was rarely observed (unpublished data).
However, we used Kreyberg-Jareg trichrom staining method
that diﬀerentially stains acid mucopolysaccharides blue and
thus contributes to better distinction between normal and
aberrant mucosa. Interestingly, the presence of neutrophils
in the epithelial lining of colon mucosa (cryptitis) and
in the lumen of crypts (crypt abscess) was reported in
DSS-treated C57BL/6OlaHsd mice when investigators used
immunoﬂuorescent staining against neutrophils [23].
Chronic changes appear few weeks after DSS appli-
cation. They consist of mononuclear leucocytes inﬁltra-
tion, crypt architectural disarray (Figure 5(a)), increas-
ing the distance (widening of the gap) between crypt
bases and muscularis mucosa, deep mucosal lymphocytosis
(Figure 4(a)), and transmural inﬂammation (Figure 6). It is
widely believed that transmural inﬂammation is infrequent
feature of DSS-induced colitis. In contrast, we observed
transmural inﬂammation in C57BL/6JOlaHsd mice as well
as in BALB/cAnNHsd mice, consonant with observation
by Melgar et al. [22]. Moreover, in chronic colitis of
C57BL/6JOlaHsd mice we even observed transmural inﬂam-
mation with lymphoid follicles (Figure 6(b)), which is
histological feature of Crohn’s disease and was until now not
observed in DSS colitis model.
Rarely reported characteristic change is also reepithe-
lisation of rectal and distal colonic erosions by squamous
epithelium that evidently originates from anal squamousJournal of Biomedicine and Biotechnology 5
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Figure 6: (a) Focal transmural chronic colitis (skip lesion). C57BL/6JOlaHsd female mice are exposed to 3% DSS solution for 5 days
followed by drinking water for 28 days. (b) Transmural inﬂammation with lymphoid follicles in subserosa (arrows) and chronic erosion.
C57BL/6JOlaHsd female mice are exposed to 3% DSS solution for 9 days followed by drinking water for 28 days. Kreyberg trichrom stain
(acid mucopolysaccharides are stained blue).
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Figure 7: (a) and (b) reepithelisation of rectal and distal colonic erosion by squamous epithelium (arrows). C57BL/6JOlaHsd male mice are
exposed to 3% DSS solution for 5 days followed by drinking water for 7 days. Kreyberg trichrom stain (acid mucopolysaccharides are stained
blue).
mucosa (Figure 7). In some slides islands of squamous
epithelium are found surrounded by colonic mucosa prox-
imally and distally, but in most cases with deeper sections
there appeared a continuity of squamous epithelium distally,
suggesting an irregular shape of a squamous cell regenerate.
Focallysometimesthereisamoderateepithelialregeneratory
atypia simulating dysplasia (Figure 5(b)). Most frequently it
is found at the edge of chronic erosions.
We observed reepithelisation of distal part of colon as
early as day 5 of DSS treatment in C57BL/6JOlaHsd but
not in BALB/cAnNHsd mice. According to our experience
reepithelisation of distal colon with squamous epithelium is
frequent observation in C57BL/6JOlaHsd mice 1–4 weeks
after DSS removal. The distance of reepithelisation with
squamous epithelium that we measured under microscope
ranged from 0.5–6.5mm of colon length.
Histological changes seen in mouse DSS-induced colitis
are the features of IBD in man, some of them of ulcerative
colitis (regular rectal localization) and some of Crohn’s dis-
ease (transmural inﬂammation with disseminated lymphoid
follicles, focal lesions) [24, 25].
Besides all in Figure 1, mentioned factors that aﬀect
features of DSS-induced colitis preparation of tissues for
histological examination may also be one of the reasons
for discrepancy among studies. According to our experience
as well as recommendation of other investigators [15]
longitudinal sections as well as at least few sections of the
same slide at intermediate distance of not less than 0.1mm
may better reﬂect the actual damage of DSS colitis than
cross sections because of the patchy nature of DSS-induced
lesions. In addition, the choice of staining method may also
aﬀect histological observations. For instance, cryptitis, crypt
abscesses as well as squamous reepithelisation are easier to
diagnose in sections stained with Kreyberg-Jareg method
than hematoxylin-eosin method.
5. The Role of IntestinalFlora in
the Pathogenesis of DSS-InducedColitis
Intestinal microﬂora and their products have been impli-
cated in the pathogenesis of human IBD [2, 26–28]a n d
in several animal models [29]. The importance of the
intestinal ﬂora is directly supported by studies of some
murine models where colitis is not observed when they
are maintained in a gnotobiotic state but rapidly emerges6 Journal of Biomedicine and Biotechnology
Table 1: Susceptibility to DSS-induced colitis among inbred strains (adapted from [15]).
Cecum Proximal colon Middle colon Distal colon
DBA/2J BC — A A
NON/LtJ AB — A A
NON.H2g7 AB — AB AB
129/SvPas A — AB B
NOD-scid D A AB BC
C57BL/6J BC A B BC
C3H/HeJ D A AB C
NOD/LtJ CD — B BC
C3H/HeJBir D A AB C
Strains that do not share the same letter in a column have signiﬁcat diﬀerences in histological score for particular part of the colon after DSS administration.
Letter A denotes the lowest histological score, while D denotes the highest histological score observed among the strains. — denotes no changes found in the
colon (normal mucosa).
when they are reconstituted with bacteria that are considered
normal constituents of luminal ﬂora (explained in detail by
Nell et al. [29]).Ithasbeendemonstratedthatintestinalﬂora
is implicated in the pathogenesis of DSS colitis in mice as
well. First who suggested contribution of colonic bacteria or
their products in the development of colitis in this model
were Okayasu et al. [13]. They observed increased numbers
of Enterobacteriaceae, Bacteroidaceae, and Clostridium spp.
in the colons of mice aﬀected by DSS colitis [13]. Another
suggestioninthisdirectionwasgivenbyHansetal.[30],who
reported that treatment with antibiotics reduced inﬁltration
of granulocytes in the mucosa and improved histological
signs of DSS colitis in acute phase [30] .T h er o l eo fc o m -
mensal bacteria and innate immunity in the development
of intestinal inﬂammation has been further demonstrated
by Hudcovic et al. [31]. When DSS-treated immunocom-
petent BALB/c and immunodeﬁcient SCID mice (lacking T
and B lymphocytes) were maintained under conventional
conditions, both strains developed substantial changes in the
colon mucosa. BALB/c mice showed complete loss of the
surface epithelium and severe inﬁltration of inﬂammatory
cells. To evaluate susceptibility to DSS colitis in gnotobiotic
conditions BALB/c and SCID mice were transferred into
isolators for germ-free rearing by special gnotobiological
techniques. Interestingly, BALB/c and SCID mice reared
in germ-free conditions (lacking any intestinal microﬂora)
developed only minor signs of mucosal inﬂammation after
DSS treatment [31]. This ﬁnding indicates that the presence
of microﬂora facilitates the inﬂammation in DSS-induced
colitis. Similar ﬁndings were observed by Kitajima et al. [32].
They used IQI/Jic mice maintained in germ-free conditions
and their littermates that were conventionalized with feces
obtained from SPF BALB/c mice three weeks before DSS
administration. Histopathological ﬁndings revealed that
IQI/Jic mice under germ-free conditions had no lesions
indicative of colitis in the large intestine 3 days after 5% DSS
treatment, while IQI/Jic mice in conventional conditions
developed focal erosions in the large bowel, mostly in the
cecum and proximal colon. Interestingly, when both groups
of mice were treated with 1% DSS for 14 days, mice under
germ-free conditions developed slight inﬂammatory cell
inﬁltration and edema in the lamina propria of the cecum
and proximal colon and sever ulcerations, hemorrhages with
frequent thrombi, and slight inﬂammatory cell inﬁltration
in the distal colon. In the large bowel of IQI/Jic mice
in conventional conditions only focal lesions of slight
inﬂammatory cells inﬁltration and edema in mucosa along
t h ew h o l el a r g eb o w e lw e r eo b s e r v e d[ 32]. These ﬁndings
demonstrate ﬁrstly that mucosal destruction caused by DSS
occurs without the involvement of intestinal microﬂora and
secondly that intestinal microﬂora may play an important
modifying role in the susceptibility and responsiveness to
DSS-induced damage of epithelial cells. The role of intestinal
microﬂora in DSS-induced colitis is further investigated in
mice deﬁcient for diﬀerent toll-like receptors (TLR), which
function as sensors of microbial infection and are critical
for the initiation of inﬂammatory and immune defence
responses [33].
6.The Role of GeneticFactorsin
the Pathogenesis of DSS-InducedColitis
Similar to IBD in humans [3], genetic factors play important
role in DSS-induced colitis. Diﬀerences in susceptibility
and responsiveness to DSS-induced colitis among inbred
strains and substrains of mice have been identiﬁed. A
quantitative histological analysis of DSS-induced colitis in
nine mouse strains using a standardized protocol (3.5% DSS
of 36–45kDa molecular weight for 5 days) demonstrated
major diﬀerences in DSS responsiveness among strains [15].
C3H/HeJ, NOD/Ltj, and NOD-scid inbred strains are very
susceptible to DSS-induced lesions, which develop in severe
form mostly in the cecum. 129/SvPas and DBA/2J inbred
mice are less susceptible to DSS-induced lesions and show
various degrees of susceptibility to DSS, depending upon
anatomical site as schematically demonstrated in the Table 1.
Interestingly, severity of DSS-induced lesions in most inbred
strains increased from proximal to the distal colon. A greater
susceptibility to DSS-induced colonic but not cecal lesions
w a so b s e r v e di nm a l em i c e[ 15].
Stevceva et al. [35] demonstrated that C3H mice are
more susceptible to DSS colitis than CBA/H and BALB/c.
C3H mice developed severe colitis with severe inﬂammatoryJournal of Biomedicine and Biotechnology 7
Table 2: Diﬀerentially expressed genes in acute phase of DSS colitis that had been previously associated with human IBD [34].
Gene Name Expression Gene Name Expression
Cytokine Genes involved in tissue remodeling
IL-6 Interleukine-6 ↑ 2.6 Mmp3 Stromelysin 1 ↑ 22.5
IL-16 Interleukine-16 ↓ 2.7 Mmp14 Membrane type 1 MMP ↑ 2.1
IL-22 Interleukine-22 ↑ 2.4 Timp1 Tissue inhibitor of metalloproteinase 1 ↑ 3.6
Chemokine Regenerating islet-derived genes
CCL2 JE (human:MCP-1) ↑ 1.8 Reg3γ Regenerating islet-derived 3γ ↑ 14.0
CCL3 MIP-1α ↑ 3.3 Pap Pancreatitis-associated protein ↑ 79.1
CCL11 Eotaxin ↑ 3.3 S-100a9 S-100 calcium-binding protein A9 (calgranulin B) ↑ 14.0
CXCL1 KC (hu: GROα) ↑ 2.9 Prostaglandin metabolism
CXCL5 LIX (hu: ENA-78) ↑ 6.6 Ptgs2 Prostaglandin-endoperoxidase synthase 2 (COX-2) ↑ 4.1
Colitis was induced in 8wk female BALB/c mice that received 3% DSS for 7 days and were sacriﬁced on day 7. ↑: signiﬁcantly increased expression by denoted
factor, ↓: signiﬁcantly decreased expression by denoted factor.
response predominantly involving ascending (proximal)
colon and cecum, while CBA/H and BALB/c mice developed
severe colitis mostly in distal colon. BALB/c mice, which are
frequently used strain in DSS-colitis, are also less susceptible
t oD S Sa sI Q I / J i c[ 32] or C57BL/6 [22]. The diﬀerences
in the susceptibility to DSS-induced lesions were either
due to genetic diﬀerences in the ability of the mucosa to
withstand inﬂammatory damage, diﬀerences in the ability to
limit the inﬂammatory response, or both. Melgar et al. [22]
demonstrated diﬀerences in the progression of DSS colitis
between two commonly used strains. After DSS withdrawal
(one cycle), BALB/c mice recovered of DSS colitis, while in
C57BL/6micecolitisprogressedintochronicphase[22].The
genetic factors contributing to DSS susceptibility in mice
are unknown. Interestingly, some strains of mice are able to
limit and eliminate DSS-induced inﬂammatory response in
colon, while inﬂammatory process in C57BL/6 mice can not
be repared but progresses into chronic form of colitis [22].
This indicates that genetic factors are importantly involved
into regulations of inﬂammatory response, which is of great
interest for further research.
7. Pathogenesis of DSS-InducedColitis
It is widely accepted that DSS is toxic to colonic epithelial
cells and causes defects in the epithelial barrier integrity,
whereby increasing the colonic mucosal permeability to
allow permeation of large molecules such as DSS. The mech-
anism of how DSS passes through the mucosal epithelial
cells (transcellularly or paracellularly mediated via tight
junctions) remains uncertain. First changes related to DSS
were observed after 1 day of DSS treatment. These changes
werelossofoneofthecomponentsoftightjunctioncomplex
[36, 37] zonula occludens-1 (ZO-1) [38] and signiﬁcantly
increased expression of proinﬂammatory cytokines (TNF-α,
IL-1β,I F N - γ, IL-10, and IL-12) in the colon [39]. By day
3 of DSS treatment signiﬁcant increase in permeability to
Evan’s blue was observed [38]. At this time ﬁrst histological
changes in the colonic mucosa in the form of basal crypts
lossandincreasedinﬂammatorycellsinﬁltrationcanbeseen.
In acute phase of DSS colitis the impairment of epithelial
barrier function is associated with loss and redistribution
of the tight junction proteins such as occludin, ZO-1 [38],
claudin-1,-3,-4,and-5andanincreasedepithelialapoptotic
ratio [40]. Altered expression of tight junction proteins and
increased epithelial apoptosis were reported also in human
IBD. It was proposed that imbalance between apoptosis
and proliferation causes relevant leaks in the epithelial
barrier. This is supported by the ﬁnding that both increased
apoptosis and decreased proliferation of the epithelium take
placeintheacutephaseofDSScolitis[41].Thesinglelayered
intestinal epithelium is a physicaland immunological barrier
that prevents direct contact of the intestinal mucosa with the
luminal microbiota.
As evidenced by the amelioration of inﬂammation in
germ-free animals and in mice treated with antibiotics
[27, 30, 31], DSS-induced breakdown of mucosal epithelial
barrier function allows the entry of luminal antigens and
microorganisms into the mucosa resulting in overwhelming
inﬂammatory response.
Microarray analysis of the gene expression revealed that
173 genes were diﬀerentially and signiﬁcantly expressed
in the colon of DSS-treated mice by a factor of two
or more when compared to control mice. Fifteen were
previouslyassociatedwithIBDinhumans(showninTable 2)
[34]. Intestinal Na+-related transporters/channels and their
regulatory proteins (NHE1,3, β-ENaC, and NHERF1,2) have
been found to be downregulated in mouse colon in acute
phase of DSS colitis and in mucosal biopsies from IBD
patients (UC or CD) in active phase of disease [44].
7.1. Inﬂammatory Response and Mediators Involved in the
Pathogenesis of DSS Colitis . Numerous inﬂammatory medi-
ators have been implicated in the pathogenesis of human
IBD. These include cytokines, eicosanoids, reactive oxygen
species, nitric oxide, and complement system activation
products[45–48].Similarly,DSS-inducedcolitisisassociated
with the upregulation of diﬀerent cytokines, chemokines,
nitric oxide [49, 50], and inducible nitric oxide synthase
(iNOS) [51]. Changes in production of inﬂammatory
mediators in DSS-treated mice were investigated during
diﬀerent phases of colitis, in the serum and/or colon and by8 Journal of Biomedicine and Biotechnology
Table 3: Proﬁle of inﬂammatory mediators in diﬀerent phases of DSS-induced colitis in mice.
Tissue/method Analytes measured acute DSS colitis chronic DSS colitis Mouse strain ref.
7d a y so fD S St r e a t m e n t
Colon/RT PCR IL-1, IL-4, IL-10,
IL-12, IFNγ,T N F α
↑ IL-1, IL-10, IL-12,
↑ IFN-γ,T N F α — BALB/c [42]
5d a y so fD S St r e a t m e n t 5d a y so fD S Sf o l l o w e db y
28 days of water
Colon/ELISA,
MSI
IL-1α,I L - 1 β,I L - 1 2
p40, IL-12 p70, IL-17,
IL-6, G-CSF, IL-18
↑ IL-1α,I L - 1 β, IL-12 p40,
↑ IL-12 p70, IL-17, IL-6,
↑ G-CSF
↑ IL-1α,I L - 1 β, IL-12 p40,
↑ IL-12 p70, IL-17, IL-6,
↑ G-CSF
C57BL/6J [22]
↑ IL-1α,I L - 1 β,I L - 6 ,
↑ IL-18, G-CSF
↑ IL-12 p40 BALB/c [22]
5d a y so fD S St r e a t m e n t 5d a y so fD S Sf o l l o w e db y7
days of water
Colon/RT PCR
TNF-α,I L - 1 β,I L - 6 ,
IL-10, IL-12, IFN-γ,
KC, MIP-2
↑ TNF-α,I L - 1 β,I L - 6 ,
↑ IL-10, IL-12, IFN-γ,
↑ KC, MIP-2
↑ TNF-α,I L - 1 β,I L - 6 ,
IL-10,
↑ IL-12, IFN-γ,K C ,M I P - 2
C57BL/6J [39]
7d a y so fD S St r e a t m e n t 4c y c l e so f7 d a y so fD S S
followed by 10 days of water
Serum/MSI
IL-1β,I L - 2 ,I L - 4 ,
IL-5, IL-6, IL-10,
IL-12, IL-17, IFN-γ,
TNF-α,G M - C S F ,
IP-10, KC, MCP-1,
MIG, MIP-1α
↑ IL-6, IL-17, TNF-α,K C ↑ IL-6, IFN-γ,I L - 4 ,I L - 1 0 [ 43]
Colon/Western IL-6, IL-12, IL-23,
IL-17, IFN-γ
↑ IL-6, IFN-γ,I L - 1 7 ↑ IL-6 C57BL/6J [43]
RT PCR: real-time PCR; MSI: multiplex sandwich immunoassay; IFN-γ: interferone gama; IL: interleukine; GM-CSF: granulocyte-macrophage colony-
stimulating factor; IP-10: interferon-inducible protein; KC: keratinocyte-derived chemokine; MCP-1: monocyte chemoattractant protein; MIG: monokine
induced by IFN-γ;M I P - 1 α: macrophage inﬂammatory protein; TNF-α: tumor necrosis factor alpha.
diﬀerent methods (shown in Table 3). Increased expression
of diﬀerent inﬂammatory mediators (TNF-α,I L - 1 β,I F N - γ,
IL-10, and IL-12) was observed as early as the ﬁrst day of
DSS treatment [39]. The production of these inﬂammatory
mediators increased progressively during DSS treatment.
Diﬀerent proﬁle of inﬂammatory mediators in acute and
chronic phase of DSS colitis was demonstrated. Acute
inﬂammation in DSS colitis converts to a predominant Th2-
mediated inﬂammatory response in the chronic state (lower
levels of TNF-α, IL-17, and KC and elevated levels of IL-
6, IFN-γ,a n dI L - 4 ,I L - 1 0 )[ 43]. Progressive upregulation in
the transcripts for Th1 cytokines (IL-12, IFN-γ,I L - 1 ,a n d
TNF-α) was observed with increasing dosage of DSS [42].
Diﬀerent cytokine proﬁle in chronic phase of DSS colitis was
found between BALB/c and C57BL/6J mice, which reﬂected
the severity of inﬂammation or inﬁltration of inﬂammatory
cells in the colon found histologically [22].
These inﬂammatory mediators not only play a role in
the pathogenesis of DSS-induced colitis but are important as
intervention targets against colitis as excellently described by
Kawada et al. [52]. Cytokine proﬁle in DSS colitis correlates
with clinical and histological parameters as well as barrier
properties. Diﬀerent expression depending on strain and
phase of colitis provides this model as a useful tool to dissect
the role of these cytokines in the induction of inﬂammation
and recovery from it.
Recently comprehensive study of mucosal and systemic
immune responses in C57BL/6OlaHsd mice exposed to 3%
DSSfor6dayshasbeenperformedusingimmunoﬂuorescent
staining and ﬂow cytometry analyses. It has been shown that
adaptive immune responses in this mouse strain are induced
during both acute and chronic phase of colitis in all organs
tested, that are, colon, spleen, and mesenteric lymph nodes
as early as day 1 of DSS treatment until the end (i.e., day 25)
[23]. Interplay of neutrophils, dendritic cells, macrophages,
and T and B cells among spleen, mesenteric lymph nodes,
and colon in DSS-treated C57BL/6OlaHsd mice in temporal
fashion is schematically represented in Figure 8.
8.GeneticalyModiﬁedMice andDSSTreatment
DSS-induced colitis is nowadays frequently used in geneti-
cally engineered mice (GEM), to study basic immunologic
mechanisms of IBD and to elucidate the role of particular
deleted (−/−) or inserted (Tg) gene in the pathogenesis of the
colitis.
Toll-like receptors (TLR) are critical receptors and
signal transducers for structurally conserved pathogen-
associated molecular patterns of bacterial cell components
(such as lipopolysaccharide) that provoke innate immune
responses by stimulating macrophages/dendritic cells to
produce proinﬂammatory cytokines. It has been shown that
mice deﬁcient for diﬀerent TLR (TLR2, TLR4) or other
molecules, which are implicated in signaling via TLR such
as myeloid diﬀerential protein (MyD88), are very susceptibleJournal of Biomedicine and Biotechnology 9
Table 4: Genetically engineered mouse models in the pathogenesis of DSS colitis.
GEM model Background (breeder) Age gender N MS MW of DSS DSS treatment End S Ref
TLR2−/−
TLR4−/−
TLR2/4−/− C57BL/10ScSn N = 10–12 nr 40kDa 3.5% for 7 days Day 8 ↑ [53]
5–8wks
TLR4−/− C57BL/6J Male, female 2.5% for 5 days Day 5
MyD88−/− (Jax) N = 5-6 nr 36–50kDa 2.5% for 5/7 days Day 12/14 ↑ [54]
TLR2−/−
TLR4−/− F2
MyD88−/− 129/SvJ × C57BL/6 SPF 40kDa 2% for 7 days Day 0–28 ↑ [33]
8wks
Male 1.2% for 8 days
MyD88−/− nr N = 10 SPF 50kDa 2.5% for 8 days Day 8 ↑ [55]
10wks
C57BL/6 Male [56, 57]
IL-18Tg (nr) N = 20 SPF 50kDa 2% for 8 days Day 12 ↑
3c y c l e so f
C57BL/6 7–9wks 2% for 5 days + Day 5
IL-15−/− (Taconic) N = 11 nr 36–50kDa 5 days of water Day 25 ↓ [58]
C57BL/6J Male, female
TNF-α−/− (Shimizu, Japan) N = 15 nr 8kDa 4.5% for 7 days Day 7 ↑ [51]
8–10wks
Male
MRP1−/− FVB N = 8 SC 40kDa 3% for 7days Day 7 ↑ [59]
C57BL/6 8-9wks Day 4, 7
Mtgr1−/− (nr) Male, female nr 40–50kDa 3% for 4days Wk 6, 10 ↑ [60]
7-8wks
C57BL/6 Male, female 3% for 5 days
SOCS-1+/− (nr) N = 14 SPF 36–50kDa (4% for 7 days) Day 14 ↑ [61]
5c y c l e so f
C57BL/6J 8–12wk 2% for 7 days +
IRF-1−/− (Jax) N = 15 nr 40kDa 7 days of water Wk 10 ↑ [62]
8–10wk
Female
PPARγΔIEpC nr N = 20 nr 35–40kDa 2.5% for 7 days Day 7 ↑ [63]
C57BL/6J
PPARγΔCD4+ (nr) N = 34 nr 36–44kDa 2.5% for 7 days Day 0,2,7 ↑ [64]
C57BL/6
TPH1−/− (Taconic) N = 10 nr 40kDa 5% for 5 days Day 5 ↓ [65]
Bk2R−/− C57BL/6 8–12wk ns
C3−/− (Jax) N = 8 nr 36–40kDa 3% for 10 days Day 10 ↓ [45]
C57BL/6 Male, female
iNOS−/− (Jax) N = 5 nr 40kDa 2.5% for 9 days Day 3,9 ↓ [49, 50]
eNOS−/− ↓
nNOS−/− 129/Sv × C57BL/6 Male, female ↑
e/nNOS−/− (Jax) N = 5 nr 40kDa 2.5% for 9 days Day 3,9 ns [49]10 Journal of Biomedicine and Biotechnology
Table 4: Continued.
GEM model Background (breeder) Age gender N MS MW of DSS DSS treatment End S Ref
5–10wks
C57BL/6 Female
APN−/− (nr) N = 5–7 nr 40kDa 2% for 5 days Day 5,10 ↓ [66]
8–10wks
C57BL/6J Male
APN−/− (Clea Japan) N = 11 SPF 36–50kDa 0.5% for 15 days Day 15 ↑ [67]
VhlΔF/F Day 5 ↑
Hif-1αΔF/F 6 – 8w k 2 . 5 %o r5 %f o r 1y e a r n s
ArntΔF/F nr nr nr 35–40kDa 5 days ns [68]
GEM: genetically engineered mice, N: number of mice pre group, MS: microbiological state, MW: molecular weight, S: susceptibility to DSS in comparison
t ow i l d - t y p em i c e( m i c eo ft h es a m es t r a i nw i t h o u td e l e t i o n ) ,↓: signiﬁcantly lower, SFP: speciﬁc pathogen-free conditions, SC: standard conditions, ns:
nonsigniﬁcant, nr: not reported, ↑: signiﬁcantly higher, wk: week, TLR: toll-like receptor, MyD88: myeloid diﬀerential protein, IL: interleukine, MRP:
multi drug resistant protein, Mtgr: myeloid translocation gene related-1, SOCS: suppressor of cytokine signaling, IRF: Interferon regulatory factor, PPAR:
peroxisome proliferator-activated receptor, TPH: tryptophan hydroxylase, Bk2R: bradykinin type 2 receptor, C3: complement, APN: adiponectine, Vhl: von
Hippel-Lindau tumor suppressor protein, Hif: hypoxia-inducible factor, Arnt: aryl hydrocarbon nuclear translocator.
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Figure 8: Schematic representation of mucosal (colon) and systemic (spleen, MLN) immune responses in C57BL/6OlaHsd mice exposed
t o3 %D S Sf o r6d a y sf o l l o w e db yw a t e rf o r1 9d a y s .M e a s u r e m e n t sw e r em a d eo nd a y0 ,1 ,3 ,5 ,8 ,1 2 ,a n d2 5a sd e n o t e db yn u m b e r s .
Schematic representation is based on results obtained by Hall et al. [23]. MLN: mesenteric lymph nodes, N: neutrophils, M: macrophages,
DC: dendritic cells, T: T cells, B: B cells.
to DSS colitis, indicating important protective role of these
molecules in colitis [33, 53–55]. Overproduction of IL-
18 or deletion of TNF-α has been shown to exacerbate
DSS colitis [51, 56]. On the other hand mice deﬁcient for
IL-15 showed reduced susceptibility to DSS colitis [58].
Mice deﬁcit for IL-12 developed mild DSS colitis, while
mice deﬁcit for IL-18 developed severe colitis associated
with high lethality [69]. Deletion of suppressor of cytokine
signaling-1 (SOCS-1), which is a negative feedback molecule
for cytokine signaling, increased susceptibility to DSS col-
itis, suggesting that SOCS-1 plays preventive role in the
development of DSS-induced colitis in mice by inhibiting
IFN-γ/STAT1 signaling [61]. Interferon regulatory factor-1
(IRF-1) is a transcription factor stimulated by IFN-γ and
TNF-α that binds to the promoter region of inﬂammation-
related genes, such as IFN-α,I F N - β, and iNOS. It is
expressed in lymphocytes, monocytes, and a wide variety of
other cell types, including enterocytes. Mice lacking IRF-1
transcription factor developed signiﬁcantly increased DSS-
induced colonic dysplasia [62]. Tryptophan hydroxylase-
1 (TPH1) catalyzes the rate-limiting step in the synthesis
of 5-hydroxytryptamine (5-HT) from tryptophan. It is anJournal of Biomedicine and Biotechnology 11
important enteric mucosal signaling molecule inﬂuencing
gut physiology (motor and secretory function) following
inﬂammation and is considered important in maintaining
intestinal homeostasis. However, mice lacking TPH1 had
signiﬁcantly reduced susceptibility to DSS colitis [65].
Taken together, GEM treated with DSS are valuable
m o d e lt ot e s td i ﬀerent molecules, which are involved in the
mediation of inﬂammation such as cytokines (IL-12, IL-
15, IL-18, TNF-α), nitric oxides (iNOS, eNOS, and nNOS),
complement system activation products or other molecules
involved in signaling of inﬂammation (SOCS-1, IRF-1), to
further identify bacterial factors involved in maintaining
intestinal homeostasis (TLR, MyD88), to investigate the role
of particular factor when totally deleted or deleted only
in particular types of cells such as intestinal, (PPARγΔIEpC;
VhlΔF/F;H if-1αΔF/F;A rnt ΔF/F)orCD4+Tcells(PPARγΔCD4+)
and to test therapeutic interventions based upon inhibition
of particular gene expression strategies (TPH1, APN, and
MRP1). In the Table 4 susceptibility to DSS-induced colitis
in mice deﬁcient for a particular gene is shown. Mouse
background, gender, microbiological state, molecular weight
of DSS, and DSS treatment, factors that importantly aﬀect
DSS colitis and need to be taken into account in designing
investigation or evaluating results, are also stated.
9. Conclusion
DSS-induced model is simple to induce and not expensive,
which makes it one of the most commonly used model of
IBD to study various aspects of IBD such as pathogenesis,
genetic predisposition to IBD, immune mechanisms, and
role of microﬂora in the pathogenesis of IBD as well
as bowel malignancy secondary to IBD. As demonstrated
above, various factors may aﬀect susceptibility to DSS and
modify results. Representative examples of how important
can be all mentioned details are studies where two groups
of researchers investigated the role of adiponectine in DSS
colitis. Both groups used in their studies the same mice
model (mice with APN deletion) exposed to DSS treatment.
They observed quite opposite results [66, 67]. It is thus
advisable to state and describe all details and conditions that
may aﬀect the DSS susceptibility.
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